Compare WLFC & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLFC | RLAY |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 1996 | 2020 |
| Metric | WLFC | RLAY |
|---|---|---|
| Price | $120.20 | $7.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 57.4K | ★ 2.3M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | ★ 17.99 | N/A |
| EPS | ★ 16.70 | N/A |
| Revenue | ★ $674,381,000.00 | $8,355,000.00 |
| Revenue This Year | $16.17 | $27.30 |
| Revenue Next Year | $4.88 | $7.43 |
| P/E Ratio | $7.35 | ★ N/A |
| Revenue Growth | ★ 29.58 | N/A |
| 52 Week Low | $114.01 | $1.78 |
| 52 Week High | $229.67 | $8.36 |
| Indicator | WLFC | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 45.62 | 64.31 |
| Support Level | $114.01 | $6.28 |
| Resistance Level | $135.00 | $8.36 |
| Average True Range (ATR) | 5.23 | 0.50 |
| MACD | 0.20 | 0.14 |
| Stochastic Oscillator | 37.38 | 76.56 |
Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).